290 related articles for article (PubMed ID: 18055477)
1. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.
Denton CP; Pope JE; Peter HH; Gabrielli A; Boonstra A; van den Hoogen FH; Riemekasten G; De Vita S; Morganti A; Dölberg M; Berkani O; Guillevin L;
Ann Rheum Dis; 2008 Sep; 67(9):1222-8. PubMed ID: 18055477
[TBL] [Abstract][Full Text] [Related]
2. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
3. [Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases].
Marotta H; Montisci R; Tiso F; Pontarollo S; Rizzo M; Tona F; Iliceto S; Cozzi F
Reumatismo; 2007; 59(4):299-303. PubMed ID: 18157286
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term bosentan in children with pulmonary arterial hypertension.
Rosenzweig EB; Ivy DD; Widlitz A; Doran A; Claussen LR; Yung D; Abman SH; Morganti A; Nguyen N; Barst RJ
J Am Coll Cardiol; 2005 Aug; 46(4):697-704. PubMed ID: 16098438
[TBL] [Abstract][Full Text] [Related]
5. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease.
Ibrahim R; Granton JT; Mehta S
Can Respir J; 2006; 13(8):415-20. PubMed ID: 17149459
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
[TBL] [Abstract][Full Text] [Related]
7. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
Valerio CJ; Handler CE; Kabunga P; Smith CJ; Denton CP; Coghlan JG
Rheumatology (Oxford); 2010 Nov; 49(11):2147-53. PubMed ID: 20675359
[TBL] [Abstract][Full Text] [Related]
10. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ
Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158
[TBL] [Abstract][Full Text] [Related]
11. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
[TBL] [Abstract][Full Text] [Related]
12. Review of bosentan in the management of pulmonary arterial hypertension.
Gabbay E; Fraser J; McNeil K
Vasc Health Risk Manag; 2007; 3(6):887-900. PubMed ID: 18200808
[TBL] [Abstract][Full Text] [Related]
13. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.
Oldfield V; Lyseng-Williamson KA
Am J Cardiovasc Drugs; 2006; 6(3):189-208. PubMed ID: 16780392
[TBL] [Abstract][Full Text] [Related]
14. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.
Ivy DD; Rosenzweig EB; Lemarié JC; Brand M; Rosenberg D; Barst RJ
Am J Cardiol; 2010 Nov; 106(9):1332-8. PubMed ID: 21029834
[TBL] [Abstract][Full Text] [Related]
16. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
17. Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
Funauchi M; Kishimoto K; Shimazu H; Nagare Y; Hino S; Yano T; Kinoshita K
Rheumatol Int; 2009 May; 29(7):769-75. PubMed ID: 19037604
[TBL] [Abstract][Full Text] [Related]
18. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.
Valerio CJ; Coghlan JG
Vasc Health Risk Manag; 2009; 5():607-19. PubMed ID: 19688101
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.
Keogh AM; McNeil KD; Wlodarczyk J; Gabbay E; Williams TJ
J Heart Lung Transplant; 2007 Feb; 26(2):181-7. PubMed ID: 17258153
[TBL] [Abstract][Full Text] [Related]
20. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
